Pages that link to "Q34562870"
Jump to navigation
Jump to search
The following pages link to Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study (Q34562870):
Displaying 50 items.
- Adverse effects of biologics: a network meta-analysis and Cochrane overview (Q24234197) (← links)
- PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions (Q26738542) (← links)
- Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis (Q26852235) (← links)
- Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies (Q26991673) (← links)
- Adalimumab for the treatment of rheumatoid arthritis (Q28282655) (← links)
- Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies (Q33260342) (← links)
- Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity (Q34027422) (← links)
- Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study (Q34076916) (← links)
- Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension (Q34607794) (← links)
- Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations (Q35026464) (← links)
- Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (Q35605643) (← links)
- Sex: a major predictor of remission in early rheumatoid arthritis? (Q35638333) (← links)
- Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values (Q35760044) (← links)
- Adalimumab in the therapy of uveitis in childhood (Q35763157) (← links)
- Genetic regulation of T regulatory, CD4, and CD8 cell numbers by the arthritis severity loci Cia5a, Cia5d, and the MHC/Cia1 in the rat (Q35919096) (← links)
- Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study (Q36513512) (← links)
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study (Q36610390) (← links)
- Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes (Q36639857) (← links)
- Adalimumab for rheumatoid arthritis (Q36708319) (← links)
- Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines (Q36724093) (← links)
- HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab (Q36786389) (← links)
- Contribution of genetic studies in rodent models of autoimmune arthritis to understanding and treatment of rheumatoid arthritis (Q36912113) (← links)
- The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts (Q37272263) (← links)
- The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents (Q37301134) (← links)
- Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis (Q37302417) (← links)
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. (Q37321296) (← links)
- Long-term use of adalimumab in the treatment of rheumatic diseases. (Q37358124) (← links)
- Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature (Q37358271) (← links)
- Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. (Q37390458) (← links)
- Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis (Q37391811) (← links)
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial (Q37465523) (← links)
- Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy (Q37663873) (← links)
- Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study (Q37691205) (← links)
- Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists (Q37714705) (← links)
- Rheumatoid arthritis therapy: advances from bench to bedside (Q37739480) (← links)
- Mechanistic medicine: novel strategies for clinical trials (Q37739484) (← links)
- Clinical experience with adalimumab in the treatment of ocular Behçet disease. (Q37756167) (← links)
- Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer (Q37773243) (← links)
- Adalimumab (humira™) in ophthalmology: a review of the literature (Q37823308) (← links)
- Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology (Q37834466) (← links)
- Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis (Q37873493) (← links)
- Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era (Q37958447) (← links)
- Biological therapies for rheumatoid arthritis: progress to date (Q38096206) (← links)
- Emerging therapies for rheumatoid arthritis (Q38110963) (← links)
- Adalimumab in the treatment of rheumatoid arthritis (Q38192659) (← links)
- Biomarkers and immunomodulation as a treatment option for chronic pain conditions (Q38198083) (← links)
- Certolizumab pegol in rheumatoid arthritis: current update (Q38198118) (← links)
- Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides (Q38238931) (← links)
- Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. (Q38406712) (← links)
- Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. (Q39603215) (← links)